“A majority of the top 10 therapy areas, which contribute 90% of the IPM, have managed to show double-digit value growth,” said Sheetal Sapale, vice president-commercial, PharmaTrac.
Among the top therapies, cardiac, anti-infectives and gastrointestinal showed relatively stronger volume growth last month, according to PharmaTrac.
In January, IPM reported about ₹16,234 crore value growth and unit growth of 2%. “On a MAT basis, the market has enumerated ₹1,94,951 crore with 7.4% value growth,” as per PharmaTrac.
A relatively higher unit growth was seen in respiratory, pain / analgesics, urology, antineoplastics and stomatologicals.
Antibiotic drug Augmentin and anti-diabetes Glycomet GP continued to be the top-selling medicine brands.”New introductions and price growth have led to the growth of the market. The anti-infective therapy area has shown sizable volume-driven growth. Majority of the top players have shown very encouraging value growth and Augmentin and Glycomet GP continue to retain their leadership position this month as well,” Sapale said.Among the four zone, west zone showed the highest unit growth of 5.5% in January. Tamil Nadu in the south, d UP in the west and Uttarakhand in the north were the highest contributing states. Telangana was the only state that demonstrated a dip of -5% in January.
(You can now subscribe to our Economic Times WhatsApp channel)
